Clinical trial
Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients With Atrial Fibrillation.
NCT04467905 is registered in ClinicalTrials.gov with Milestone Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients With Atrial Fibrillation.
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 19, 2020
- Completion date
- August 10, 2023
- Enrollment
- 69 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.